Progyny Quarterly Income Statement
NASDAQ: PGNYHealth CareMisc Health and Biotechnology ServicesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Progyny revenue and earnings
In the quarter ended Jun 30, 2026, Progyny generated $350.5 million in revenue, up 5.3% from the same quarter a year earlier. Net income was $28.1 million (+63.9% year over year), for a net margin of 8.0% versus a median of 4.6% in the prior 5 quarters. Gross margin was 25.5% (up from 23.7%) and operating margin 11.4%.
Diluted earnings per share came in at $0.34, up from $0.19.
Summary generated from market data by MetaCap's automated system. Methodology
Progyny income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 350.51M | 328.50M | 318.40M | 313.35M | 332.87M | 324.04M | 298.43M | 286.63M | 304.09M | 278.08M | 269.94M | 280.89M |
| Revenue growth (YoY) | +5.30% | +1.38% | +6.69% | +9.32% | +9.47% | +16.53% | +10.55% | +2.04% | +8.85% | +7.62% | +25.95% | +36.77% |
| Cost of Revenue | 261.21M | 245.43M | 241.52M | 240.51M | 253.90M | 248.24M | 235.00M | 227.38M | 235.81M | 215.67M | 213.05M | 218.27M |
| Gross Profit | 89.30M | 83.07M | 76.88M | 72.83M | 78.97M | 75.80M | 63.43M | 59.24M | 68.28M | 62.41M | 56.89M | 62.62M |
| Operating Expenses | 49.30M | 47.69M | 61.66M | 51.31M | 54.62M | 51.63M | 47.65M | 46.79M | 47.59M | 43.88M | 43.09M | 44.44M |
| Research & Development | 3.30M | 2.80M | 3.10M | 2.60M | 2.30M | 1.50M | — | — | — | — | — | — |
| Selling, General & Admin | 49.30M | 47.69M | 61.66M | 51.31M | 54.62M | 51.63M | 47.65M | 46.79M | 47.59M | 43.88M | 43.09M | 44.44M |
| Operating Income | 40.00M | 35.38M | 15.22M | 21.53M | 24.36M | 24.17M | 15.79M | 12.46M | 20.69M | 18.52M | 13.80M | 18.19M |
| Other Income (Expense) | 1.13M | 1.50M | 2.63M | 2.44M | 2.72M | 2.37M | 1.87M | 5.50M | 4.38M | 3.99M | 2.46M | 2.74M |
| Pretax Income | 41.14M | 36.88M | 17.85M | 23.96M | 27.08M | 26.54M | 17.66M | 17.96M | 25.07M | 22.52M | 16.26M | 20.93M |
| Income Tax | 13.09M | 12.65M | 5.37M | 10.10M | 9.96M | 11.48M | 7.13M | 7.54M | 8.58M | 5.62M | 2.79M | 5.03M |
| Net Income | 28.05M | 24.23M | 12.48M | 13.86M | 17.11M | 15.06M | 10.53M | 10.42M | 16.48M | 16.90M | 13.47M | 15.90M |
| Net Income growth (YoY) | +63.93% | +60.91% | +18.54% | +33.04% | +3.80% | -10.88% | -21.81% | -34.45% | +9.97% | -4.41% | +295.25% | +20.34% |
| EPS (Basic) | 0.36 | 0.30 | 0.15 | 0.16 | 0.20 | 0.18 | 0.12 | 0.12 | 0.18 | 0.18 | 0.14 | 0.17 |
| EPS (Diluted) | 0.34 | 0.29 | 0.14 | 0.15 | 0.19 | 0.17 | 0.12 | 0.11 | 0.17 | 0.17 | 0.13 | 0.16 |
| Shares Outstanding (Basic) | 78.17M | 80.92M | 85.23M | 86.02M | 85.77M | 85.50M | 85.81M | 90.07M | 93.87M | 96.48M | 95.98M | 95.50M |
| Shares Outstanding (Diluted) | 82.14M | 84.76M | 89.46M | 90.23M | 89.64M | 89.31M | 88.91M | 93.82M | 97.84M | 101.05M | 100.75M | 100.88M |
| EBITDA | 41.63M | 36.86M | 16.59M | 22.80M | 25.56M | 25.28M | 16.66M | 13.29M | 21.44M | 19.24M | 14.43M | 18.77M |
| Gross Margin | 25.48% | 25.29% | 24.15% | 23.24% | 23.72% | 23.39% | 21.26% | 20.67% | 22.45% | 22.44% | 21.08% | 22.29% |
| Operating Margin | 11.41% | 10.77% | 4.78% | 6.87% | 7.32% | 7.46% | 5.29% | 4.35% | 6.80% | 6.66% | 5.11% | 6.48% |
| Net Margin | 8.00% | 7.38% | 3.92% | 4.42% | 5.14% | 4.65% | 3.53% | 3.64% | 5.42% | 6.08% | 4.99% | 5.66% |
This table shows 12 quarterly periods of Progyny's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow PGNY's reporting calendar. What is a income statement?